Dross
05-31-2007, 10:34 AM
A new story entry has been added:
Doctors conclude temsirolimus is effective new treatment for advanced renal cell carcinoma
The results of a phase III, randomized clinical study involving patients with advanced renal cell carcinoma and poor prognostic features show temsirolimus improved overall survival when compared to the current treatment for this stage of disease. The study, led by Gary R. Hudes, M.D., director of the Genitourinary Malignancies Program at Fox Chase Cancer Center, is published in the May 31 issue of the New England Journal of Medicine. A total of 626 patients with renal cell carcinoma (RCC) were enrolled in the study and received one of three treatments – a new drug called temsirolimus, an older drug called interferon, or both the new and old drugs together. The patients who received temsirolimus alone survived longer than those who received interferon, the usual or ‘standard’ treatment for this disease.
Doctors conclude temsirolimus is effective new treatment for advanced renal cell carcinoma
The results of a phase III, randomized clinical study involving patients with advanced renal cell carcinoma and poor prognostic features show temsirolimus improved overall survival when compared to the current treatment for this stage of disease. The study, led by Gary R. Hudes, M.D., director of the Genitourinary Malignancies Program at Fox Chase Cancer Center, is published in the May 31 issue of the New England Journal of Medicine. A total of 626 patients with renal cell carcinoma (RCC) were enrolled in the study and received one of three treatments – a new drug called temsirolimus, an older drug called interferon, or both the new and old drugs together. The patients who received temsirolimus alone survived longer than those who received interferon, the usual or ‘standard’ treatment for this disease.